Clinical Trials
61 trialsExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
DP-04
AstraZeneca
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Eastern Cooperative Oncology Group
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
iCaRe2
University of Nebraska
ANTARES
Instituto do Cancer do Estado de São Paulo
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Navigation Intervention for Adolescent and Young Adult Cancer Survivors
Kaiser Permanente
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Sichuan Enray Pharmaceutical Sciences Company
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Improving Care for Rural Patients With Solid Tumors
University of Colorado, Denver
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
CAMPERR
Adela, Inc
AYAConnect
UNC Lineberger Comprehensive Cancer Center
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
KEYNOTE 158
Merck Sharp & Dohme LLC
MOLTHYSO
Institut Bergonié
EARN
Washington University School of Medicine
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
AMPLIFY
University of Alabama at Birmingham
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
ACROPOLI
SOLTI Breast Cancer Research Group
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Universidade Federal de Pernambuco
ROOT
Taproot Health
QUANTUM
VitaMed Research LLC
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Beijing Friendship Hospital
CAPABLE-IT
Istituti Clinici Scientifici Maugeri SpA
AcSé
UNICANCER
A Follow-up Study of Women Evaluated and Treated for Infertility
National Institutes of Health Clinical Center (CC)
OPTI-DOSE
University Medical Center Groningen
ALpha-T
Hoffmann-La Roche
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Genmab
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
RESTORE
Blue Note Therapeutics
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Lumos Pharma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
Zhujiang Hospital
E3N
Institut National de la Santé Et de la Recherche Médicale, France
SIGNATURE
Novartis